Institutional

PBE

Equity | Sector Equity

Invesco Dynamic Biotechnology & Genome ETF

Product Details

The Invesco Dynamic Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex℠ Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Index is comprised of securities of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

as of 12/31/2020 12/31/2020

Performance

Index History (%) YTD 1Yr 3Yr 5Yr 10Yr Since Inception
Dynamic Biotech & Genome Intellidex Index 26.37 26.37 14.78 7.23 13.03 11.20
S&P Composite 1500 Biotechnology Index 9.90 9.90 6.78 4.74 18.13 13.23
Fund History (%)
Fund NAV 25.50 25.50 14.15 6.99 12.68 10.82
After Tax Held 25.46 25.46 14.14 6.91 12.58 10.75
After Tax Sold 15.09 15.09 11.10 5.45 10.61 9.29
Fund Market Price 25.69 25.69 14.15 6.97 12.67 10.82
Index History (%) YTD 1Yr 3Yr 5Yr 10Yr Since Inception
Dynamic Biotech & Genome Intellidex Index 26.37 26.37 14.78 7.23 13.03 11.20
S&P Composite 1500 Biotechnology Index 9.90 9.90 6.78 4.74 18.13 13.23
Fund History (%)
Fund NAV 25.50 25.50 14.15 6.99 12.68 10.82
After Tax Held 25.46 25.46 14.14 6.91 12.58 10.75
After Tax Sold 15.09 15.09 11.10 5.45 10.61 9.29
Fund Market Price 25.69 25.69 14.15 6.97 12.67 10.82

Market returns are based on the midpoint of the bid/ask spread at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times. Performance data quoted represents past performance, which is not a guarantee of future results. Investment returns and principal value will fluctuate, and shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than performance data quoted. After-tax returns reflect the highest federal income tax rate but exclude state and local taxes. Fund performance reflects applicable fee waivers, absent which, performance data quoted would have been lower. After Tax Held and After Tax Sold are based on NAV. Returns less than one year are cumulative.

as of 09/30/2020

Growth of $10,000

Data beginning 10 years prior to the ending date of 09/30/2020. Fund performance shown at NAV.

An investor cannot invest directly in an index. The results assume that no cash was added to or assets withdrawn from the Index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.

as of 01/14/2021

Market Cap & Style Allocations

Large-Cap Value 4.68%
Large-Cap Blend -
Large-Cap Growth 4.23%
Mid-Cap Value 2.73%
Mid-Cap Blend 9.79%
Mid-Cap Growth 23.75%
Small-Cap Value 7.35%
Small-Cap Blend 12.06%
Small-Cap Growth 35.41%

as of 01/15/2021 Top Holdings | View All

Fund Holdings subject to change

Ticker Company % of Fund
NTLA Intellia Therapeutics Inc 5.21
ALXN Alexion Pharmaceuticals Inc 5.17
CTLT Catalent Inc 4.96
RGEN Repligen Corp 4.89
TECH Bio-Techne Corp 4.67
QGEN QIAGEN NV 4.64
BIIB Biogen Inc 4.62
SGEN Seagen Inc 4.58
FLGT Fulgent Genetics Inc 4.24
VRTX Vertex Pharmaceuticals Inc 4.23
The characterizations of distributions reflected in this table are as of the date noted below. The actual amounts of income, capital gains and return of capital for tax purposes are only determined after the Fund’s fiscal year end, and may differ from the amounts and characterizations reflected in the chart below. Please refer to the Tax Center for the most current and/or final characterizations of these distributions, including any distributions characterized as return of capital.

Distributions | HideView All | Distribution Information

Ex-Date Record Date Pay Date $/
Share
Ordinary Income Short Term Gains Long Term Gains Return of Capital Liquidation Distribution
03/23/2020 03/24/2020 03/31/2020 0.02898 0.02898 - - - -
09/24/2018 09/25/2018 09/28/2018 0.00207 0.00207 - - - -
06/16/2017 06/20/2017 06/30/2017 0.21532 0.21532 - - - -
03/17/2017 03/21/2017 03/31/2017 0.05552 0.05552 - - - -
12/16/2016 12/20/2016 12/30/2016 0.12080 0.12080 - - - -
09/16/2016 09/20/2016 09/30/2016 0.02834 0.02834 - - - -
06/17/2016 06/21/2016 06/30/2016 - - - - - -
03/18/2016 03/22/2016 03/31/2016 - - - - - -
12/18/2015 12/22/2015 12/31/2015 0.30821 0.30821 - - - -
09/18/2015 09/22/2015 09/30/2015 0.13655 0.13655 - - - -
06/19/2015 06/23/2015 06/30/2015 0.12270 0.12270 - - - -
03/20/2015 03/24/2015 03/31/2015 - - - - - -
09/19/2014 09/23/2014 09/30/2014 0.04290 0.04290 - - - -
06/20/2014 06/24/2014 06/30/2014 0.23404 0.23404 - - - -
09/20/2013 09/24/2013 09/30/2013 0.00000 0.00000 - - - -
06/21/2013 06/25/2013 06/28/2013 0.00000 0.00000 - - - -
03/15/2013 03/19/2013 03/28/2013 0.00000 0.00000 - - - -
12/21/2012 12/26/2012 12/31/2012 0.00000 0.00000 - - - -
09/21/2012 09/25/2012 09/28/2012 0.00000 0.00000 - - - -
06/15/2012 06/19/2012 06/29/2012 0.00000 0.00000 - - - -
03/16/2012 03/20/2012 03/30/2012 0.00000 0.00000 - - - -
12/18/2009 12/22/2009 12/31/2009 0.07553 0.07553 - - - -

Frequency Distribution of Discounts & Premiums

    Bid/Ask MidPoint Above NAV
Quarter
Ending
Days 0.00-
0.25%
0.26-
0.50%
0.51-
0.99%
1.00-
1.49%
1.50-
1.99%
≥2.00%
12/31/2020 64 23 3 1 0 0 0
09/30/2020 64 22 3 0 0 0 0
06/30/2020 63 14 12 0 0 0 0
03/31/2020 62 23 0 0 0 0 0
Year Ended 2020 253 82 18 1 0 0 0
    Bid/Ask Midpoint Below NAV
Quarter
Ending
Days 0.00-
0.25%
0.26-
0.50%
0.51-
0.99%
1.00-
1.49%
1.50-
1.99%
≥2.00%
12/31/2020 64 33 3 1 0 0 0
09/30/2020 64 33 6 0 0 0 0
06/30/2020 63 28 9 0 0 0 0
03/31/2020 62 32 5 1 1 0 0
Year Ended 2020 253 126 23 2 1 0 0

Fund Inception : 06/23/2005

Shareholders may pay more than net asset value when they buy Fund shares and receive less than net asset value when they sell those shares, because shares are bought and sold at current market prices. Performance data quoted represents past performance, which is not a guarantee of future results.

Premiums/Discounts

Shareholders may pay more than net asset value when they buy Fund shares and receive less than net asset value when they sell those shares, because shares are bought and sold at current market prices. Performance data quoted represents past performance, which is not a guarantee of future results.

 Risk & Other Information

Typically, security classifications used in calculating allocation tables are as of the last trading day of the previous month.

There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. The Fund's return may not match the return of the Underlying Index. The Fund is subject to certain other risks. Please see the current prospectus for more information regarding the risk associated with an investment in the Fund.

Investments focused in a particular industry, such as biotechnology, are subject to greater risk. and are more greatly impacted by market volatility, than more diversified investments.

Stocks of small and mid-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to resale.

The Fund is non-diversified and may experience greater volatility than a more diversified investment.

The fund may engage in frequent trading of its portfolio securities in connection with the rebalancing or adjustment of the Underlying Index.

The S&P Composite 1500® Biotech (S&P Biotech) Index consists of all biotechnology stocks included in the S&P Composite 1500® Index.

The Global Industry Classification Standard was developed by and is the exclusive property and a service mark of MSCI, Inc. and Standard & Poor's.

ICE Data Indices, LLC, is used with permission. Dynamic Biotech & Genome IntellidexSM Index (“Index”) is a service/trade mark of ICE Data Indices, LLC or its affiliates and has been licensed for use by Invesco Capital Management LLC, in connection with the Invesco Dynamic Biotechnology & Genome ETF (the “Product”). Neither Invesco Capital Management LLC, Invesco Exchange-Traded Fund Trust nor the Product, as applicable, is sponsored, endorsed, sold or promoted by ICE Data Indices, LLC, its affiliates or its Third Party Suppliers (“ICE Data and its Suppliers”).  ICE Data and its Suppliers make no representations or warranties regarding the advisability of investing in securities generally, in the Product particularly, the Trust or the ability of the Index to track general market performance. Past performance of an Index is not an indicator of or a guarantee of future results.

ICE DATA AND ITS SUPPLIERS DISCLAIM ANY AND ALL WARRANTIES AND REPRESENTATIONS, EXPRESS AND/OR IMPLIED, INCLUDING ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, INCLUDING THE INDICES, INDEX DATA AND ANY INFORMATION INCLUDED IN, RELATED TO, OR DERIVED THEREFROM (“INDEX DATA”). ICE DATA AND ITS SUPPLIERS SHALL NOT BE SUBJECT TO ANY DAMAGES OR LIABILITY WITH RESPECT TO THE ADEQUACY, ACCURACY, TIMELINESS OR COMPLETENESS OF THE INDICES AND THE INDEX DATA, WHICH ARE PROVIDED ON AN “AS IS” BASIS AND YOUR USE IS AT YOUR OWN RISK.

Beta is a measure of risk representing how a security is expected to respond to general market movements. Smart Beta represents an alternative and selection index based methodology that seeks to outperform a benchmark or reduce portfolio risk, or both. Smart beta funds may underperform cap-weighted benchmarks and increase portfolio risk.